Morgan Stanley lowered the firm’s price target on Idexx Laboratories to $596 from $620 and keeps an Overweight rating on the shares. The firm is lowering its 2024 EPS view to $11.08 from $11.18 following the latest earnings print.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Sees Leadership Transition and Shareholder Approval
- Idexx Laboratories price target lowered to $570 from $655 at Barclays
- Idexx Laboratories cuts FY24 EPS view to $10.82-$11.20 from $10.84-$11.33
- Idexx Laboratories reports Q1 EPS $2.81, consensus $2.67
- Idexx Laboratories price target lowered to $595 from $600 at BofA
